Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...

The global Age-related Macular Degeneration drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion ...

Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...

BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen ...

Regeneron Pharmaceuticals is a leading biotech firm with a strong portfolio. Click here to know what justifies a Buy rating ...

Regeneron’s stock $REGN dipped about 4% on Tuesday following a loss in its legal battle with Amgen over competitors to its ...

Headlines,Regeneron Pharmaceuticals' shares fell by 4.63% following a court ruling.,The decision involved a legal dispute ...

Regeneron sued Amgen in January, alleging that it was developing a biosimilar that violated key patent protections for Eylea.

A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar ...

29 August 2024 Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the ...

Investing.com -- Regeneron Pharmaceuticals (NASDAQ: REGN) shares are down a further 4% Tuesday, with analysts turning more ...

Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for ...